APMD (Apnimed) ROCE %: 204.46% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed ROCE %?

Apnimed APMD +13.64% 8 ROCE % is 204.46% as of Mar. 2026. GuruFocus rates APMD with a GF Score™ of 8/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Apnimed's annualized ROCE % for the quarter that ended in Mar. 2026 was 204.46%.

Apnimed  (NAS:APMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Apnimed ROCE % Related Terms

Apnimed ROCE % Historical Data

* Premium members only.

The historical data trend for Apnimed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed ROCE % Chart

Apnimed Annual Data
Trend Dec24 Dec25
ROCE %
-170.85 -372.95

Apnimed Quarterly Data
Dec24 Mar25 Dec25 Mar26
ROCE % 0.00 -162.19 0.00 204.46
APMD
8GF Score
Apnimed Inc APMD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apnimed ROCE % Calculation

Apnimed's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-53.818/( ( (109.223 - 42.359) + (72.873 - 110.876) )/ 2 )
=-53.818/( (66.864+-38.003)/ 2 )
=-53.818/14.4305
=-372.95 %

Apnimed's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=272.176/( ( (72.873 - 110.876) + (342.634 - 38.389) )/ 2 )
=272.176/( ( -38.003 + 304.245 )/ 2 )
=272.176/133.121
=204.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 204.46% mean?
Apnimed (APMD) has a ROCE % of 204.46% as of Mar. 2026.
Is Apnimed's ROCE % too high?
Apnimed's current ROCE % is 204.46%. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's ROCE % compare to ?
Apnimed's ROCE % of 204.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Apnimed's current ROCE % is 204.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current ROCE % of 204.46%. The current ROCE % is 204.46%. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Apnimed (APMD), the current ROCE % is 204.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price